Mehlika Toy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1364323/publications.pdf

Version: 2024-02-01

38	813	16	28
papers	citations	h-index	g-index
38	38	38	1389
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Cost-Effectiveness of 1-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States. Clinical Infectious Diseases, 2022, 74, 210-217.	5.8	36
2	The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia. Liver International, 2022, 42, 16-25.	3.9	7
3	Letter to the editor: Importance of universal screening for chronic hepatitis B infection in adults in the United States. Hepatology, 2022, 75, 1062-1063.	7.3	2
4	Cost-Effectiveness of Hepatitis B Testing and Vaccination of Adults Seeking Care for Sexually Transmitted Infections. Sexually Transmitted Diseases, 2022, 49, 517-525.	1.7	4
5	The case for simplifying and using absolute targets for viral hepatitis elimination goals. Journal of Viral Hepatitis, 2021, 28, 12-19.	2.0	28
6	Hepatitis Delta Virus Epidemiology in the Industrialized World. AIDS Reviews, 2021, 22, 203-212.	1.0	9
7	Hepatitis Delta Virus Infection: A Large Burden After All?. Journal of Infectious Diseases, 2020, 221, 1573-1575.	4.0	6
8	Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income. Value in Health, 2020, 23, 1552-1560.	0.3	16
9	Causes and trends in liver disease and hepatocellular carcinoma among men and women who received liver transplants in the U.S., 2010-2019. PLoS ONE, 2020, 15, e0239393.	2.5	26
10	Hepatitis B cure. Current Opinion in HIV and AIDS, 2020, 15, 208-212.	3.8	2
11	Title is missing!. , 2020, 15, e0239393.		0
12	Title is missing!. , 2020, 15, e0239393.		0
13	Title is missing!. , 2020, 15, e0239393.		0
14	Title is missing!. , 2020, 15, e0239393.		0
15	Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016–30. The Lancet Global Health, 2019, 7, e1180-e1188.	6.3	58
16	Economic Analyses to Inform and Support Health Policy for Chronic Hepatitis B Treatment. Current Hepatology Reports, 2019, 18, 357-362.	0.9	1
17	Knowledge, attitudes and medical practice regarding hepatitis B prevention and management among healthcare workers in Northern Vietnam. PLoS ONE, 2019, 14, e0223733.	2.5	30
18	The Hep B Calculator: an online tool for cost-effectiveness analyses of treatment. The Lancet Gastroenterology and Hepatology, 2019, 4, 668.	8.1	4

#	Article	IF	CITATIONS
19	Knowledge, attitudes and practices of hepatitis B prevention and immunization of pregnant women and mothers in northern Vietnam. PLoS ONE, 2019, 14, e0208154.	2.5	23
20	Barriers to Disease Monitoring and Liver Cancer Surveillance Among Patients with Chronic Hepatitis B in the United States. Journal of Community Health, 2019, 44, 610-625.	3.8	11
21	Racial/ethnic- and county-specific prevalence of chronic hepatitis B and its burden in California. Hepatology, Medicine and Policy, 2018, 3, 6.	1.7	8
22	Population Health And Economic Impacts Of Reaching Chronic Hepatitis B Diagnosis And Treatment Targets In The US. Health Affairs, 2018, 37, 1033-1040.	5.2	13
23	Trends in Prevalence and Predictors of Hepatitis B Virus Vaccination in the General United States Population from 1999-2014. Gastroenterology, 2017, 152, S1052.	1.3	1
24	County and Ethnic-Specific HBV Prevalence and Total Disease Burden in California: Estimates by Disease Status Using Community-Based Real-World Data. Gastroenterology, 2017, 152, S1083.	1.3	0
25	Emerging Technologies for Point-of-Care Management of HIV Infection. Annual Review of Medicine, 2015, 66, 387-405.	12.2	97
26	Recent advances in micro/nanotechnologies for global control of hepatitis B infection. Biotechnology Advances, 2015, 33, 178-190.	11.7	38
27	Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China. PLoS ONE, 2015, 10, e0139876.	2.5	22
28	Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China. Hepatology, 2014, 60, 46-55.	7.3	41
29	Preventing hepatocellular carcinoma: the crucial role of chronic hepatitis B monitoring and antiviral treatment. Hepatic Oncology, 2014, 1, 255-257.	4.2	3
30	Cost-effectiveness of viral hepatitis B & Damp; C treatment. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 973-985.	2.4	12
31	Cost-effectiveness of Augmenting Universal Hepatitis B Vaccination With Immunoglobin Treatment. Pediatrics, 2013, 131, e1135-e1143.	2.1	39
32	A Mathematical Approach for Evaluating Markov Models in Continuous Time without Discrete-Event Simulation. Medical Decision Making, 2013, 33, 767-779.	2.4	15
33	The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. European Journal of Health Economics, 2012, 13, 663-676.	2.8	24
34	Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infectious Diseases, 2011, 11, 337.	2.9	72
35	Screening and Early Treatment of Migrants for Chronic Hepatitis B Virus Infection Is Cost-Effective. Gastroenterology, 2010, 138, 522-530.	1.3	110
36	Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B. Hepatology, 2009, 50, 743-751.	7.3	27

MEHLIKA TOY

#	Article	IF	CITATIONS
37	Transmission routes of hepatitis B virus infection in chronic hepatitis B patients in The Netherlands. Journal of Medical Virology, 2008, 80, 399-404.	5.0	25
38	Costs and health impact of delayed implementation of a national hepatitis B treatment program in China. Journal of Global Health, $0,12,$	2.7	3